Abstract: Disclosed are methods, systems, and articles of manufacture for implementing an electronic design with high-capacity design closure. A reduced netlist may be generated for an analysis view of an electronic design based at least in part upon logic of interest in the analysis view. A closure may be performed based at least in part upon a union netlist, wherein the union netlist is generated from the reduced netlist. The electronic design may then be implemented based at least in part upon a result of the closure task.

Abstract: This disclosure relates to dosage regimens for targeted TGF-? inhibition with a bi-functional fusion protein for use in a method of treating biliary tract cancer or inhibiting biliary tract tumor growth in treatment naïve patients, or patients with locally advanced or metastatic BTC who have failed or are intolerant to first-line systemic chemotherapy.

Abstract: This disclosure relates generally to dosage regimens for targeted TGF-? inhibition with a bi-functional fusion protein for use in a method of treating a treatment naïve patient diagnosed with stage III non-small cell lung cancer (NSCLC), and/or mitigating a pathological condition associated with chemotherapy and radiotherapy (cCRT).

Abstract: This disclosure relates generally to methods for treating a subject diagnosed with advanced non-small-cell lung cancer (NSCLC), involving targeted TGF-? inhibition with a bi-functional fusion protein, in combination with administration of systemic chemotherapeutic agents, wherein the combination of the bi-functional fusion protein of the present disclosure with systemic chemotherapeutic agents enhances anticancer efficacy over systemic chemotherapeutic agents alone.

Abstract: This disclosure relates to dosage regimens for targeted TGF-? inhibition with a bi-functional fusion protein for use in a method of treating cancer or inhibiting tumor growth in treatment naïve patients.

Abstract: This disclosure relates generally to body weight independent (BW-independent) dosing regimens and dosage forms of a bifunctional protein targeting human protein Programmed Death Ligand 1 (PD-L1) and Transforming Growth Factor ? (TGF?).

Abstract: A system and method for generating standard delay format (SDF) files is disclosed. For each timing closed hierarchical instance, timing arcs on internal register to register paths may be marked as zero delay arcs. If the zero delay causes a hold violation, an adjustment may be computed to fix the violation. If the adjustment does not cause a setup violation, the adjustment may be applied to the end point register.

Abstract: A method of timing analysis of an integrated circuit (IC) design with a partition block including an original clock signal with a pair of clock paths having an external common point outside the block boundary is disclosed, including receiving a netlist of the partition block of a hierarchical IC design, analyzing a pair of clock paths having the external common point to determine first and second clock ports at the boundary of the partition block; and for the first and second clock ports, creating launch and capture clocks, making exclusive clock groups of the launch clock and the capture clock for opposing clock ports to avoid the launch and capture clocks for each port affecting other internal data paths within the partition block, and associating common path pessimism removal information with a source latency of the capture clock to adjust timing at an end point of the internal data path.